Author

A. Hicks

Institution: Entrada Therapeutics, Inc. (United States)

Observed institution: Entrada Therapeutics, Inc. (United States)

OpenAlex ID: A5003196012

433P Therapeutic potential of ENTR-601-44, an Endosomal Escape Vehicle (EEV™) - Oligonucleotide Conjugate for the treatment of exon 44 skip amenable DMD

2024 · M. Oldham, N. Estrella, et al. · Neuromuscular Disorders · 4

P.194 Development of a novel, EEV-Conjugated PMO for Duchenne muscular dystrophy

2022 · N. Kreher, A. Kumar, et al. · Neuromuscular Disorders · 3

P20 Endosomal Escape Vehicles (EEV™) - Oligonucleotides conjugates produce exon skipping and dystrophin production in preclinical models of Duchenne muscular dystrophy

2023 · M. Girgenrath, N. Estrella, et al. · Neuromuscular Disorders · 1

654PPreclinical efficacy of ENTR-601-50, a novel EEV™-oligonucleotide construct for the treatment of exon 50 skip-amenable Duchenne muscular dystrophy

2025 · M. Girgenrath, N. Estrella, et al. · Neuromuscular Disorders

431P Exon 45 skipping and dystrophin production with ENTR-601-45 in preclinical models of Duchenne muscular dystrophy

2024 · M. Girgenrath, N. Estrella, et al. · Neuromuscular Disorders

O.14 EEV-Conjugated PMO results in nuclear foci reduction and aberrant splicing correction in myotonic dystrophy cell and animal models

2022 · M. Grigenrath, N. Estrella, et al. · Neuromuscular Disorders

Works count: 6

Citation count: 8

H-index: 2

I10-index: